Tapan M. Kadia, MD

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

Tapan M. Kadia, MD evaluates the use of uproleselan, an E-selectin antagonist, in combination with LDAC and Cladribine in patients with treated secondary acute myeloid leukemia.

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Tapan M. Kadia, MD, discusses the utilization of uproleselan with chemotherapy in relapsed/refractory acute myeloid leukemia.